ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

SEDA Experts Strengthens Corporate Governance and Global Commercial Strategy Expertise with Addition of Daniel P. Brindle

New York, NY, July 25, 2025 (GLOBE NEWSWIRE) -- SEDA Experts LLC, a leading expert witness firm providing world-class financial expert witness services, announced today that Daniel P. Brindle joined the firm as Managing Director.

“We are thrilled to welcome Daniel to SEDA Experts,” said Damiano Colnago, Managing Partner of SEDA Experts. “His deep expertise in corporate governance, international strategy, and healthcare innovation—particularly across Asia-Pacific—brings tremendous value to our clients navigating complex global markets. Daniel’s proven leadership in both the public and private sectors further strengthens our ability to deliver strategic, high-impact advisory services.”

Daniel Brindle is a seasoned global executive with over 30 years of leadership experience across the life sciences sector, public affairs, and international law. With recognized expertise in China and the broader Asia-Pacific region, he has held senior roles at leading pharmaceutical companies including Novartis, Pfizer, and GSK, where he led commercial strategy, shaped policy engagement, and fostered cross-sector collaboration to expand access to healthcare and advance innovation.

Most recently, Mr. Brindle served as President of Novartis Group China, where he oversaw five business entities and led a team of approximately 8,500 employees. In this role, he was responsible for formulating and executing the company’s integrated strategy in one of its most strategically important global markets. His leadership focused on strengthening policy dialogue, enhancing market access, and building strategic partnerships across government, academia, and industry to support the delivery of innovative, value-based healthcare solutions.

Prior to Novartis, Mr. Brindle held senior executive roles in public affairs, policy, and business development at Eli Lilly, Pfizer, and GSK, where he led external engagement efforts across Asia-Pacific and emerging markets. His work included high-level policy initiatives, intellectual property strategy, pricing and reimbursement negotiations, and the establishment of public-private partnerships with health authorities and regulatory agencies.

In addition to his corporate leadership, Mr. Brindle served as CEO of Cheerland Biotechnology, a China-based biotechnology company, and was a partner at ZY Partners, a prominent Chinese law firm focused on corporate and intellectual property law. Earlier in his career, he served as Legislative Counsel for a U.S. Senator, advising on international affairs.

Mr. Brindle has been actively involved in shaping regional and global health policy through contributions to initiatives such as the APEC Life Sciences Innovation Forum, the Thai Center for Excellence in Life Sciences (TCELS), and the US-ASEAN Business Council. His career is distinguished by a consistent ability to navigate complex geopolitical environments and foster alignment among diverse stakeholders.

About SEDA Experts LLC

SEDA is a leading expert witness firm specializing in financial services. We support international law firms by offering the highest level of expertise across the financial industry and providing access to the most influential financial services industry leaders. We provide superior independent advice, data analytics, valuation, and elite expert reports and testimony services to law firms, regulators, and leading financial institutions.


Name: Damiano Colnago
Email: dcolnago@sedaexperts.com
Job Title: Managing Partner

Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.54
+0.00 (0.00%)
AAPL  274.11
+0.00 (0.00%)
AMD  207.58
+0.00 (0.00%)
BAC  55.33
+0.00 (0.00%)
GOOG  309.32
+0.00 (0.00%)
META  647.51
+0.00 (0.00%)
MSFT  474.82
+0.00 (0.00%)
NVDA  176.29
+0.00 (0.00%)
ORCL  184.92
+0.00 (0.00%)
TSLA  475.31
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.